Key TakeawaysCEO Jason Hollar offloaded 124,529 shares worth $29.4 million on August 18, marking his first open-market transaction since August 2025Combined insider sales from senior leadership totaled approximately $60 million in the wake of the earnings announcementShares reached an all-time closing high of $240.26 on August 11 following fourth-quarter earnings per share of $2.91, surpassing expectations of $2.42The stock has retreated from its peak, opening Friday at $229.48 after touching an intraday high of $258.30Wall Street analysts hold a “Moderate Buy” rating with a mean price target of $266.56In a significant move, Cardinal Health’s Chief Executive Officer Jason Hollar divested $29.4 million in CAH shares on August 18, mere days following the pharmaceutical distributor’s impressive performance that drove shares to unprecedented levels. The healthcare giant’s stock achieved a record closing price of $240.26 on August 11 and peaked intraday at $258.30.Cardinal Health, Inc., CAHHollar’s transactions were completed within a price range of $234.07 to $238.065 per share. Notably, this represents his inaugural open-market disposition since August 2025 and merely his second stock sale since assuming leadership at Cardinal in 2020.The CEO wasn’t operating in isolation. A coordinated series of stock sales by senior executives occurred simultaneously on the same date, collectively amounting to approximately $60 million in aggregate value.Chief Financial Officer Aaron Alt disposed of 42,000 shares, generating proceeds exceeding $9.9 million. Jessica Mayer, serving as Chief Legal and Compliance Officer, sold 29,436 shares valued at nearly $7 million. Michelle Greene, the company’s Chief Information Officer, offloaded 11,650 shares for $2.7 million.Division Leaders Join Selling WaveLeadership of Cardinal’s primary operating divisions also participated in the stock reduction. Debbie Weitzman, who heads the pharmaceutical segment, sold 7,354 shares generating approximately $1.7 million. Steve Mason, leading the global medical products and distribution division, divested 35,000 shares worth roughly $8.3 million, dramatically reducing his ownership position by nearly 66%.Mary Scherer, Chief Accounting Officer, sold 2,302 shares valued at approximately $546,472 on August 19. Collectively, company insiders disposed of 210,271 shares valued at nearly $49.6 million throughout the most recent quarter.This selling activity followed Cardinal’s fourth-quarter financial results announced on August 11, which significantly exceeded projections. Earnings per share registered at $2.91, substantially above the consensus forecast of $2.42. Revenue climbed 5.8% on a year-over-year basis to $63.67 billion, although falling slightly below analyst projections of $65.15 billion.Management also established fiscal year 2027 EPS guidance ranging from $12.40 to $12.60, providing additional momentum for the initial stock rally. Current analyst consensus forecasts full-year EPS at $12.54.Wall Street Maintains Positive OutlookNotwithstanding the stock retreat and executive selling activity, the broader investment community continues to express confidence in Cardinal’s prospects. TD Cowen elevated its price objective to $280 while reaffirming a “buy” recommendation. Leerink Partners established a $292 price target. Royal Bank of Canada launched coverage with an “outperform” designation and a $276 target.JPMorgan increased its target from $215 to $260 while maintaining a “neutral” stance. Sixteen analysts recommend buying the stock, with three suggesting holding. The consensus price target stands at $266.56.CAH commenced Friday trading at $229.48, representing a decline from its post-earnings peak. The 12-month low stands at $145.87. Cardinal has also announced a quarterly dividend distribution of $0.5158 per share, scheduled for October 15 payment to shareholders registered as of October 1, yielding 0.9%.The post Cardinal Health (CAH) Stock: CEO and Executives Dump $60M After Record Rally appeared first on Blockonomi.